Opening the record…
Opening the record…
This row at the top of printed page 310 continues the surplus medicines and equipment table begun on page 309. Al-Amal National Oncology Hospital lists Gemcitabine 1000 mg vial and Uromitexan 400 mg amp, report 14841 dated 5 June 2025, paragraph 1-b. The unlabeled extraction fields are not separate numeric metrics.
| Report paragraph | Oncology hospital | Material or equipment | Report no. & date | Department continuation cell (blank in source) |
|---|---|---|---|---|
1-ب | مستشفي الامل الوطني لعلاج الاورام | Gemcitabine 1000mg Vial Uromitexan 400mg Amp | (14841) في 2025/6/5 | — |
FEDERAL BOARD OF SUPREME AUDIT · ANNUAL REPORT 2025 · Printed page 310 · UNIT none · CSV ↓
Originally transcribed in two passes and compared cell by cell; printed totals were checked where available. Agreement between passes does not guarantee a correct reading. Source review has corrected transcription errors; unresolved readings remain marked. The 2025 report includes earlier financial years and dated observations, not a current account of every institution. English names are the desk’s renderings; the Arabic is authoritative. Dollar equivalents are illustrative at a fixed IQD 1,500/$ reference (CBI purchases from the Finance Ministry under Cabinet Resolution 544, effective 7 October 2026; 1,300 before that date). This is not the historical exchange rate for the audited fiscal year, a market quote, or the rate offered to bank customers. Download the CSV · All tables
Source: the 713-page report copy used for these tables · FBSA annual-report archive ↗. The archived copy is identified by SHA-256 d73671625d4f… . On 5 October 2026, the official archive required a security check, so a fresh copy could not be compared with this registered edition. References open this edition at the PDF page; annex numbering restarts at 1. The illustrative conversion reference is documented in the CBI circular of 8 February 2023.